Sector
PharmaceuticalsCMP
as on 03 Jul, 2024 12:00:00 AM
Open
₹1,132Prev. Close
₹1,131.6Turnover(Lac.)
₹10,965.96Day's High
₹1,172.8Day's Low
₹1,12852 Week's High
₹1,374.652 Week's Low
₹737.5Book Value
₹252.57Face Value
₹1Mkt Cap (₹ Cr.)
29,263.51P/E
47.59EPS
24.3Divi. Yield
0.177 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
10 Nov 2023
12:00 AM
Dividend
Dividend Amount: 2
Record Date: 22 Nov, 2023
5 Jul 2023
12:00 AM
AGM
Announcement Date: 05 Jul, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 25.37 | 25.37 | 25.37 | 37.21 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 5,851.93 | 5,450.39 | 4,727.35 | 3,640.33 |
Net Worth | 5,877.3 | 5,475.76 | 4,752.72 | 3,677.54 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 5,399.36 | 5,139.16 | 4,337.82 | 3,193.4 |
yoy growth (%) | 5.06 | 18.47 | 35.83 | 2.93 |
Raw materials | -1,763.12 | -1,582.48 | -1,480.7 | -1,112.48 |
As % of sales | 32.65 | 30.79 | 34.13 | 34.83 |
Employee costs | -1,089.63 | -948.84 | -870.79 | -712.78 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 1,088.36 | 1,379.96 | 784.97 | 282.8 |
Depreciation | -204.1 | -187.72 | -178.69 | -174.36 |
Tax paid | -217.42 | -239.19 | -132.51 | -49.69 |
Working capital | 484.48 | 421.93 | 376.59 | 222.97 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 5.06 | 18.47 | 35.83 | 2.93 |
Op profit growth | -17.84 | 65.46 | 107.12 | 2.25 |
EBIT growth | -21.07 | 73.34 | 160.98 | 8.97 |
Net profit growth | -23.65 | 74.84 | 179.89 | 23.8 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 7,705.04 | 6,244.32 | 5,829.79 | 5,419.99 | 4,648.71 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 7,705.04 | 6,244.32 | 5,829.79 | 5,419.99 | 4,648.71 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 124.77 | 125.62 | 66.57 | 62.84 | 67 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,521.8 | 120.29 | 3,65,682.64 | 867.6 | 0.89 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,558.95 | 76.97 | 1,21,312.5 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,479 | 32.36 | 1,20,195.02 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,099 | 31.35 | 1,08,114.81 | 1,405.2 | 0.28 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,459 | 24.48 | 1,06,298.05 | 1,034.8 | 0.63 | 5,081.8 | 1,453.02 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman / Executive Director / M D / Promoter
Premchand Godha
Joint Managing Director & CFO
A K Jain
ED / MD / CEO / Promoter
Pranay Godha
Executive Director
Prashant Godha
Independent Non Exe. Director
Anand T Kusre
Independent Non Exe. Director
Manisha Premnath
Independent Non Exe. Director
Kamal Kishore Seth
Independent Non Exe. Director
Narendra Mairpady
Company Sec. & Compli. Officer
Harish P Kamath
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Ipca Laboratories Ltd
Summary
Ipca Laboratories Limited (IPCA) was incorporated on 19th October, 1949 under the name of The Indian Pharmaceutical Combine Association Limited. Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 APIs covering various therapeutic segments. The products of the Company are now sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations for the world market.Ipcas APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries. Ipca is one of the biggest manufacturers in the world of APIs Atenolol (Antihypertensive), Chloroquine Phosphate (Antimalarial), Furosemide (Diuretic) and Pyrantel Salts (Anthelmintic) right from the basic stage. Ipca is also one of the largest suppliers of these APIs and their intermediates world over. The name of the company was changed to Ipca Laboratories Limited in 6th August of the year 1964 and again name was changed to Ipca Laboratories Private Limited in 13th January of the year 1966. Ipca had commissioned one of the first modern Pharma factory of yesteryears
Read More
What is the Ipca Laboratories Ltd share price today?
The Ipca Laboratories Ltd shares price on nse is Rs.₹1153.45 today.
What is the Market Cap of Ipca Laboratories Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ipca Laboratories Ltd is ₹29263.51 Cr. as of 03 Jul ‘24
What is the PE and PB ratio of Ipca Laboratories Ltd?
The PE and PB ratios of Ipca Laboratories Ltd is 47.59 and 4.62 as of 03 Jul ‘24
What is the 52 Week High and Low of Ipca Laboratories Ltd?
The 52-week high/low is the highest and lowest price at which a Ipca Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ipca Laboratories Ltd is ₹737.5 and ₹1374.6 as of 03 Jul ‘24
What is the CAGR of Ipca Laboratories Ltd?
Ipca Laboratories Ltd's CAGR for 5 Years at 18.57%, 3 Years at 3.94%, 1 Year at 51.55%, 6 Month at 1.64%, 3 Month at -8.26% and 1 Month at 0.38%.
What is the shareholding pattern of Ipca Laboratories Ltd?
The shareholding pattern of Ipca Laboratories Ltd is as follows:
Promoters - 46.30 %
Institutions - 44.88 %
Public - 8.82 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
